钆特酸葡甲胺在2岁以下儿科受试者中的药代动力学、疗效和安全性研究
这项IV期开放标签前瞻性研究在9个中心纳入45例2岁以下肾功能正常儿童,单次静脉注射钆特酸葡甲胺0.1 mmol/kg,用群体药代动力学分析显示清除率随eGFR增加,无需调整剂量;在28例脑、脊柱及相关组织MRI中,增强后图像对病灶显示有改善,13例(28.9%)发生26次不良事件,1例(2.2%)出现与药物相关的中度皮疹。
要点
- 2岁以下儿童单次注射0.1 mmol/kg钆特酸葡甲胺无需调整剂量。
- 增强后图像可改善脑、脊柱及相关组织病灶的边缘、内部形态和对比增强显示。
- 13例(28.9%)发生不良事件,1例(2.2%)出现药物相关中度皮疹。
核心结论
- 钆特酸葡甲胺0.1 mmol/kg单次静脉注射的药代动力学特征在2岁以下新生儿和婴儿中描述适当,无需调整剂量;增强MRI对脑、脊柱及相关组织的疗效改善和良好安全性在该人群中也得到证明。
研究设计与样本
- IV期开放标签前瞻性研究,在9个中心(4个国家)纳入45例2岁以下、估算肾小球滤过率正常且计划行常规钆增强MRI的儿童,单次静脉注射钆特酸葡甲胺0.1 mmol/kg;通过随机分配的时间点采集3份血样进行群体药代动力学分析。
关键影像表现/征象
- 在28例脑、脊柱及相关组织MRI受试者中,增强前图像显示15例受试者28个病灶,增强前+增强后图像显示16例受试者30个病灶。
- 病灶显示在受试者水平平均(SD)评分提高:病灶边界勾画0.7(1.0),内部形态0.9(1.6),对比增强3.1(3.2)。
诊断标准与关键数值
- 体重调整后的中位总清除率为0.06 L/h/kg,随估算肾小球滤过率按幂模型增加。
- 体重调整后的中位稳态分布容积(Vss)为0.047 L/kg。
- 估计的中位终末半衰期(t1/2β)为1.35 h,中位全身暴露(曲线下面积)为1591 μmol h/L。
- 注射后13例受试者(28.9%)发生26次不良事件,其中1例受试者(2.2%)报告3次严重不良事件;1例受试者(2.2%)出现1次中度皮疹,认为与钆特酸葡甲胺相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The primary objective of this study was to investigate the pharmacokinetic profile of gadoterate meglumine in pediatric patients younger than 2 years; the secondary objectives were to document its efficacy and safety.
MATERIAL AND METHODS: This was a Phase IV open-label, prospective study conducted in 9 centers (4 countries). Forty-five patients younger than 2 years with normal estimated glomerular filtration rate and scheduled to undergo routine gadolinium-enhanced magnetic resonance imaging (MRI) of any organ were included and received a single intravenous injection of gadoterate meglumine (0.1 mmol/kg). To perform the population pharmacokinetics analysis, 3 blood samples per subject were drawn during 3 time windows at time points allocated by randomization.
RESULTS: Gadoterate meglumine concentrations were best fitted using a 2-compartmental model with linear elimination from central compartment. The median total clearance adjusted to body weight was estimated at 0.06 L/h per kg and increased with estimated glomerular filtration rate according to a power model. The median volume of distribution at steady state (Vss) adjusted to body weight was estimated at 0.047 L/kg. Estimated median terminal half-life (t1/2β) was 1.35 h, and the median systemic exposure (area under the curve) was 1591 μmol h/L. Efficacy was assessed by comparing precontrast +postcontrast images to precontrast images in a subset of 28 subjects who underwent an MRI examination of brain, spine, and associated tissues. A total of 28 lesions were identified and analyzed in 15 subjects with precontrast images versus 30 lesions in 16 subjects with precontrast + postcontrast images. Lesion visualization was improved with a mean (SD) increase in scores at subject level of 0.7 (1.0) for lesion border delineation, 0.9 (1.6) for internal morphology, and 3.1 (3.2) for contrast enhancement. Twenty-six adverse events occurred postinjection in 13 subjects (28.9%), including 3 serious reported in 1 subject (2.2%). One subject (2.2%) experienced 1 rash of moderate intensity considered as related to gadoterate meglumine.
CONCLUSIONS: The pharmacokinetic profile of gadoterate meglumine after a single intravenous injection of 0.1 mmol/kg was appropriately described in newborns and infants younger than 2 years, for whom no dose adjustment is required. The improved efficacy of gadoterate meglumine for contrast-enhanced MRI examination of brain, spine, and associated tissues, as well as its good safety profile, was also demonstrated in this population.
引用
- Scala M, Koob M, de Buttet S, et al. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years. Invest Radiol. 2018. PMID: 28906338. doi:10.1097/RLI.0000000000000412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。